Related to Studies Suggest that When It Comes to Drug Development Success, Size Matters

• Lonza Eyes CHF 10M Expansion of Singapore Biopharmaceutical Development Facility
  
• Ambit Scores $30M to Advance Kinase Inhibitor Pipeline
  
• Quintiles Invests in Kareus for Phase I Trials of Alzheimer and Type 2 Diabetes Treatments
  
• Synageva Merges with Trimeris in All-Stock Deal
  
• ImmunoGen Gets $2M with Bayer Filing IND for Cancer Drug
  
• Sanofi and Audion Ink Hearing Loss Research Deal
  
• The Leukemia & Lymphoma Society to Help Epizyme with Drug for Mixed Lineage Leukemia
  
• Lilly to Invest Millions into Multispecific Therapeutics R&D
  
• GSK, Lilly Venture Funds Join in Nimbus Discovery’s $24M Series A Financing Round
  
• Acetylon Raises $27M to Push Lead HDAC Inhibitor into Phase I/II Cancer Trials
  
• AstraZeneca and PTC Ally On Small Molecule Drugs against Cancer
  
• Envoy Awarded MJFF Grant to Develop Oral Drug for Parkinson Disease
  
• SARcode Bioscience Raises $44M for Phase III Evaluation of Topical Dry Eye Syndrome Drug
  
• Pfizer to Pay $49.8M for Icagen to Pad Focus on Pain Therapy
  
• BMS Adds Another Pearl to Its String with $325M Acquisition of Amira for Fibrosis Program
  
• Merck & Co. and Simcere Form JV to Expand Access to Drugs in China
  
• Pfizer Establishes Center for Therapeutic Innovation Partnership with UC San Diego
  
• Intercept Signs Potentially $163M Diabetes Drug Development Deal with Servier
  
• Genentech Pays Array $28M Up Front for ChK-1 Anticancer Drug Deal
  
• FDA Green-Lights Roche’s Melanoma Drug and Companion Diagnostic